Establishment Labs (NASDAQ:ESTA) Price Target Raised to $86.00

Establishment Labs (NASDAQ:ESTA) had its price target upped by Needham & Company LLC from $84.00 to $86.00 in a research note published on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

A number of other research firms have also issued reports on ESTA. JPMorgan Chase & Co. increased their target price on Establishment Labs from $71.00 to $80.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a research report on Monday, December 29th. Canaccord Genuity Group boosted their target price on shares of Establishment Labs from $72.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. BTIG Research upped their target price on shares of Establishment Labs from $81.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday, December 31st. Finally, Citigroup lifted their price target on shares of Establishment Labs from $62.00 to $75.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $87.00.

Establishment Labs Stock Performance

Shares of ESTA stock opened at $77.15 on Tuesday. The company has a current ratio of 3.33, a quick ratio of 2.10 and a debt-to-equity ratio of 15.06. The company has a market cap of $2.24 billion, a PE ratio of -44.34 and a beta of 0.99. The company’s fifty day simple moving average is $71.21 and its 200-day simple moving average is $58.00. Establishment Labs has a 52 week low of $26.56 and a 52 week high of $83.31.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 197.22%. The firm had revenue of $64.62 million during the quarter, compared to analysts’ expectations of $63.80 million. During the same period in the prior year, the company earned ($1.19) EPS. The firm’s revenue was up 45.2% on a year-over-year basis. As a group, equities research analysts anticipate that Establishment Labs will post -2.41 EPS for the current year.

Institutional Trading of Establishment Labs

Several institutional investors have recently added to or reduced their stakes in the stock. Quarry LP bought a new position in Establishment Labs during the 3rd quarter valued at $34,000. Kestra Advisory Services LLC acquired a new stake in shares of Establishment Labs in the 4th quarter valued at about $47,000. State of Wyoming bought a new position in shares of Establishment Labs during the third quarter worth about $71,000. Osaic Holdings Inc. lifted its position in shares of Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after purchasing an additional 1,800 shares during the last quarter. Finally, CWM LLC grew its stake in Establishment Labs by 45.9% in the second quarter. CWM LLC now owns 2,182 shares of the company’s stock worth $93,000 after purchasing an additional 686 shares in the last quarter. 72.91% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Establishment Labs

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: Multiple brokerages raised price targets and kept bullish ratings — Canaccord raised its target to $90 and kept a Buy rating, Stephens raised to $90 with an Overweight, Mizuho lifted to $100 with an Outperform, and BTIG moved to $88 with a Buy — reinforcing analyst conviction and upside. Analyst Price Target Raises (Benzinga)
• Positive Sentiment: Q4 2025 results beat expectations: revenue (~$64.6M) and EPS beat consensus, with year‑over‑year revenue growth (~45%) — results and commentary underpin the recent analyst upgrades. Q4 2025 Earnings Call Summary (Yahoo)
• Positive Sentiment: Management provided 2026 guidance targeting at least 25% revenue growth and emphasized expansion of minimally invasive platforms — a clear growth thesis that supports higher valuation if execution continues. 2026 Revenue Guidance & Platform Expansion (MSN)
• Neutral Sentiment: Company announced a leadership transition framed as supporting the next phase of growth — this is management-level news to monitor for execution risk but not an immediate negative. Leadership Transition (Yahoo)
• Neutral Sentiment: Analyst note roundup summarizes 11 analysts’ views — useful context on street sentiment and target dispersion but adds no single new catalyst. Analyst Roundup: 11 Analysts (Benzinga)
• Negative Sentiment: Market reaction: shares are trading lower today despite the earnings beat, guidance and several price‑target raises — suggests some profit‑taking or skepticism about margins/near‑term profitability. Market Reaction

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.